These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 21646575)

  • 61. Decrease in REM latency and changes in sleep quality parallel serotonergic damage and recovery after MDMA: a longitudinal study over 180 days.
    Kirilly E; Molnar E; Balogh B; Kantor S; Hansson SR; Palkovits M; Bagdy G
    Int J Neuropsychopharmacol; 2008 Sep; 11(6):795-809. PubMed ID: 18261250
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Long-term neurotoxic effects of MDMA result in cortical and hippocampal structural changes].
    Li SX; Li J; Wang X; Peng ZG; Kuang WH; Huang MS
    Sheng Li Xue Bao; 2006 Feb; 58(1):34-40. PubMed ID: 16489401
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender.
    de Win MM; Reneman L; Reitsma JB; den Heeten GJ; Booij J; van den Brink W
    Psychopharmacology (Berl); 2004 May; 173(3-4):376-82. PubMed ID: 14726997
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [¹⁸F]Altanserin and small animal PET: impact of multidrug efflux transporters on ligand brain uptake and subsequent quantification of 5-HT₂A receptor densities in the rat brain.
    Kroll T; Elmenhorst D; Matusch A; Celik AA; Wedekind F; Weisshaupt A; Beer S; Bauer A
    Nucl Med Biol; 2014 Jan; 41(1):1-9. PubMed ID: 24120220
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serotonin 2A receptor agonist binding in the human brain with [(11)C]Cimbi-36: Test-retest reproducibility and head-to-head comparison with the antagonist [(18)F]altanserin.
    Ettrup A; Svarer C; McMahon B; da Cunha-Bang S; Lehel S; Møller K; Dyssegaard A; Ganz M; Beliveau V; Jørgensen LM; Gillings N; Knudsen GM
    Neuroimage; 2016 Apr; 130():167-174. PubMed ID: 26876490
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels.
    Spies M; Nasser A; Ozenne B; Jensen PS; Knudsen GM; Fisher PM
    Hum Brain Mapp; 2020 Nov; 41(16):4518-4528. PubMed ID: 32697408
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serotonin transporter expression is not sufficient to confer cytotoxicity to 3,4-methylenedioxymethamphetamine (MDMA) in vitro.
    Hayat S; Williams RJ; Rattray M
    J Psychopharmacol; 2006 Mar; 20(2):257-63. PubMed ID: 16510483
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Acceleration of serotonin transporter transport-associated current by 3,4-methylenedioxymethamphetamine (MDMA) under acidic conditions.
    Yamauchi Y; Izumi T; Unemura K; Uenishi Y; Nakagawa T; Kaneko S
    Neurosci Lett; 2007 Nov; 428(2-3):72-6. PubMed ID: 17949903
    [TBL] [Abstract][Full Text] [Related]  

  • 69. PET imaging of serotoninergic neurotransmission with [(11)C]DASB and [(18)F]altanserin after focal cerebral ischemia in rats.
    Martín A; Szczupak B; Gómez-Vallejo V; Plaza S; Padró D; Cano A; Llop J
    J Cereb Blood Flow Metab; 2013 Dec; 33(12):1967-75. PubMed ID: 23982048
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effects of MDMA and related analogs on plasma 5-HT: relevance to 5-HT transporters in blood and brain.
    Yubero-Lahoz S; Ayestas MA; Blough BE; Partilla JS; Rothman RB; de la Torre R; Baumann MH
    Eur J Pharmacol; 2012 Jan; 674(2-3):337-44. PubMed ID: 22079770
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A PET study of effects of chronic 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on serotonin markers in Göttingen minipig brain.
    Cumming P; Møller M; Benda K; Minuzzi L; Jakobsen S; Jensen SB; Pakkenberg B; Stark AK; Gramsbergen JB; Andreasen MF; Olsen AK
    Synapse; 2007 Jul; 61(7):478-87. PubMed ID: 17415793
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB.
    Frankle WG; Narendran R; Huang Y; Hwang DR; Lombardo I; Cangiano C; Gil R; Laruelle M; Abi-Dargham A
    Biol Psychiatry; 2005 Jun; 57(12):1510-6. PubMed ID: 15953487
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission.
    Reneman L; Booij J; Schmand B; van den Brink W; Gunning B
    Psychopharmacology (Berl); 2000 Feb; 148(3):322-4. PubMed ID: 10755746
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Direct comparison of [(18) F]MH.MZ and [(18) F] altanserin for 5-HT2A receptor imaging with PET.
    Hansen HD; Ettrup A; Herth MM; Dyssegaard A; Ratner C; Gillings N; Knudsen GM
    Synapse; 2013 Jun; 67(6):328-37. PubMed ID: 23390031
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET.
    Buchert R; Obrocki J; Thomasius R; Väterlein O; Petersen K; Jenicke L; Bohuslavizki KH; Clausen M
    Nucl Med Commun; 2001 Aug; 22(8):889-97. PubMed ID: 11473208
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Increased anxiety 3 months after brief exposure to MDMA ("Ecstasy") in rats: association with altered 5-HT transporter and receptor density.
    McGregor IS; Clemens KJ; Van der Plasse G; Li KM; Hunt GE; Chen F; Lawrence AJ
    Neuropsychopharmacology; 2003 Aug; 28(8):1472-84. PubMed ID: 12700695
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The new PET imaging agent [11C]AFE is a selective serotonin transporter ligand with fast brain uptake kinetics.
    Zhu Z; Guo N; Narendran R; Erritzoe D; Ekelund J; Hwang DR; Bae SA; Laruelle M; Huang Y
    Nucl Med Biol; 2004 Nov; 31(8):983-94. PubMed ID: 15607480
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serotonin transporter availability in thalamic subregions in schizophrenia: a study using 7.0-T MRI with [(11)C]DASB high-resolution PET.
    Kim JH; Son YD; Kim JH; Choi EJ; Lee SY; Lee JE; Cho ZH; Kim YB
    Psychiatry Res; 2015 Jan; 231(1):50-7. PubMed ID: 25465315
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.
    Liechti ME; Saur MR; Gamma A; Hell D; Vollenweider FX
    Neuropsychopharmacology; 2000 Oct; 23(4):396-404. PubMed ID: 10989266
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
    Green AR; Mechan AO; Elliott JM; O'Shea E; Colado MI
    Pharmacol Rev; 2003 Sep; 55(3):463-508. PubMed ID: 12869661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.